Publicaciones en las que colabora con DAVID FRAGUAS HERRÁEZ (15)

2023

  1. Differences in Patterns of Stimulant Use and Their Impact on First-Episode Psychosis Incidence: An Analysis of the EUGEI Study

    Schizophrenia Bulletin, Vol. 49, Núm. 5, pp. 1269-1280

  2. The relationship between genetic liability, childhood maltreatment, and IQ: findings from the EU-GEI multicentric case–control study

    Social Psychiatry and Psychiatric Epidemiology, Vol. 58, Núm. 10, pp. 1573-1580

2021

  1. The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis

    Psychopharmacology, Vol. 238, Núm. 3, pp. 665-676

2020

  1. Birth weight and antipsychotic induced weight gain: A prenatal programming approach in the PEPs study

    Schizophrenia Research, Vol. 218, pp. 292-294

  2. The Positive and Negative Syndrome Scale for Schizophrenia Autism Severity Scale (PAUSS) in young people with autism and schizophrenia

    Revista de Psiquiatria y Salud Mental, Vol. 13, Núm. 3, pp. 118-130

2019

  1. Dietary Interventions for Autism Spectrum Disorder: A Meta-analysis

    Pediatrics, Vol. 144, Núm. 5

  2. Neuroanatomical deficits shared by youth with autism spectrum disorders and psychotic disorders

    Human Brain Mapping, Vol. 40, Núm. 5, pp. 1643-1653

2017

  1. Atypical age-dependency of executive function and white matter microstructure in children and adolescents with autism spectrum disorders

    European Child and Adolescent Psychiatry, Vol. 26, Núm. 11, pp. 1361-1376

2014

  1. A longitudinal study on the relationship between duration of untreated psychosis and executive function in early-onset first-episode psychosis

    Schizophrenia Research, Vol. 158, Núm. 1-3, pp. 126-133

  2. Duration of untreated psychosis predicts functional and clinical outcome in children and adolescents with first-episode psychosis: A 2-year longitudinal study

    Schizophrenia Research, Vol. 152, Núm. 1, pp. 130-138

  3. Second-generation antipsychotic use in children and adolescents: A six-month prospective cohort study in drug-naïve patients

    Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 53, Núm. 11, pp. 1179-1190.e4

2012

  1. Plasma antioxidant capacity is reduced in Asperger syndrome

    Journal of Psychiatric Research, Vol. 46, Núm. 3, pp. 394-401

2011

  1. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons

    European Neuropsychopharmacology, Vol. 21, Núm. 8, pp. 621-645

2010

  1. Évolution des modifications cérébrales au cours des psychoses précoces

    Information Psychiatrique, Vol. 86, Núm. 6, pp. 513-527

2008

  1. Longitudinal brain changes in early-onset psychosis

    Schizophrenia Bulletin, Vol. 34, Núm. 2, pp. 341-353